| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3804 |
| Trial ID | NCT06314828 |
| Disease | B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | RJMty19 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Phase 1, Open-label, Single Arm Clinical Trial to Evaluate the Tolerability, Safety and Efficacy of RJMty19 in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) |
| Year | 2024 |
| Country | China |
| Company sponsor | Guangdong Ruishun Biotech Co., Ltd |
| Other ID(s) | RJMty19-B-NHL002 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||
|
|||||||||||